NBP · I-Mab

The appointment of Mark Hagler as President and Chief Commercial Officer represents a strategic reinforcement of NovaBridge’s leadership team at a critical inflection point: both lead assets — givastomig and VIS-101 — are transitioning from mid-stage proof-of-concept to pivotal development. Hagler’s background is explicitly tied to high-value therapeutic areas aligned with the company’s pipeline: oncology (e.g., Abraxane®, Afinitor®) and ophthalmology (Sun Pharma’s Ophthalmology division turnaround). His prior responsibilities — including global launch leadership, commercial readiness for IND-to-commercialization assets, pricing and market access strategy — directly address known execution risks for biotech companies advancing first-in-class candidates without established commercial infrastructure. The press release emphasizes his role in shaping clinical trial design and business development discussions, suggesting integration beyond traditional commercial functions into core R&D and partnership strategy. While no compensation terms are disclosed, the timing — immediately following positive Phase 1b data for givastomig and ahead of a Phase 2b readout for VIS-101 — signals investor-facing preparation for value inflection points in 2026–2027. As a foreign private issuer filing on Form 6-K, NovaBridge does not use 8-K Item codes; the event maps cleanly to SEC Item 5.02 (Executive Changes) under Regulation S-K.